Please tell us what you thought about today’s presentation by taking the survey below:
Challenges in the treatment of agitation associated with Alzheimer’s Dementia (AAD) presents across multiple treatment settings. As the prevalence of Alzheimer’s Dementia continues to significantly increase, Primary Care will play an important role in not only assessing for cognitive declines in older adults but also in managing the diagnosis and treatment of AAD. This webinar will dive into the unmet needs within this patient population and feature experts in the management of AAD within the primary care setting. Specifically, presenters will review the prevalence of AAD, describe challenges in diagnosing AAD, and explore the potential pathobiological correlates in AAD. The webinar will discuss the clinical and humanistic burden of AAD, as well as highlight the current guidelines for nonpharmacological and pharmacological treatments of this complex and prominent complication of an already devastating disease.
Director and Principal Investigator for Connecticut Clinical Research in Cromwell, Connecticut
Medical Science Liaison
Senior Medical Science Liaison
Speaker Dr. C. Brendan Montano is a paid consultant for Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)
Speakers Elika Hefazi, PharmD, BCPP and Beth DiNapoli, PhD are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)
Notifications
